Bevacizumab, Breast Cancer, Molecular Targeted Therapy, Neoadjuvant Chemotherapy
Conditions
Keywords
bevacizumab, neoadjuvant chemotherapy, HER2-negative breast cancer
Brief summary
\- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.
Interventions
DRUGbevacizumab
The patients will be treated with Avastin combined neoadjuvant chemotherapy
Sponsors
Roche Pharma AG
LiNanlin,Ph.D, Chief Physician,Clinical Professor
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* HER2-negative breast cancer patients * Without surgery * Plans to neoadjuvant chemotherapy
Exclusion criteria
* HER2-positive breast cancer patients * Post-operative patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | From enrollment to disease progression | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall response | From enrollment to disease progression | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
Countries
China
Contacts
Primary ContactNanlin Li, Phd
Backup ContactHongyu Xiao, Master
Outcome results
None listed